Drug Discovery & DDS– category –
-
Drug Discovery & DDS
Drug Discovery & DDS Weekly Report June 28, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report June 28, 2026 (PDF) — Download Weekly Report June 28, 2026 (PDF) — DownloadDownload 🎙 Podcast June 28, 2026 (... -
Drug Discovery & DDS
Ionis Forges $30M Ex-US Rare Disease Pact with Recordati, Accelerating Global ASO Reach
Fierce Biotech USA Overview Ionis Pharmaceuticals has secured a $30 million upfront payment from Recordati, granting the Italian firm exclusive ex-US development and commercialization rights for specific rare disease therapies. This stra... -
Drug Discovery & DDS
Boehringer Ingelheim Fuels Immunai’s AI with $15M to Unlock T-Cell Secrets for Cancer, Autoimmune Drug Discovery
Fierce Biotech USA Overview Boehringer Ingelheim (BI) has invested $15 million in Immunai's advanced AI platform, initiating a collaborative research agreement. This partnership aims to accelerate drug discovery for cancer and autoimmune... -
Drug Discovery & DDS
Otsuka’s ADHD Therapy Poised for FDA Approval Following Successful Phase 3b Clinical Trial
Fierce Biotech USA Overview Otsuka Pharmaceutical announced positive outcomes from its Phase 3b clinical trial for an Attention-Deficit/Hyperactivity Disorder (ADHD) treatment, marking a crucial step ahead of its U.S. Food and Drug Admin... -
Drug Discovery & DDS
Elixirgen Therapeutics and Nippon Shinyaku Forge Alliance for Next-Gen DMD Therapy EXG-7001
GlobeNewswire Japan Overview Elixirgen Therapeutics and Nippon Shinyaku have signed an option agreement for the development and commercialization of EXG-7001, a promising therapeutic candidate for Duchenne Muscular Dystrophy (DMD). This ... -
Drug Discovery & DDS
Bayer and Iambic Therapeutics Partner to Drive Small Molecule Drug Discovery with AI Platform
BioSpace USA Overview Bayer has announced a strategic collaboration with Iambic Therapeutics, leveraging Iambic's advanced AI platforms, Enchant and NeuralPLexer, for small molecule drug discovery. This partnership aims to significantly ... -
Drug Discovery & DDS
Biotech CEOs Anticipate Funding Rebound by Late 2026, Pin Hopes on FDA for Streamlined Drug Development
Endpoints News USA Overview A recent Endpoints 100 survey reveals 62% of biotech CEOs anticipate a significant improvement in the funding environment by late 2026, driven by a recovering IPO market and increased M&A activity. These l... -
Drug Discovery & DDS
Antares and Novartis Forge $1.9B Deal to Tackle ‘Undruggable’ Cancer Targets with Small Molecules
Business Wire USA Overview Antares Therapeutics and Novartis have announced a strategic collaboration to discover, develop, and commercialize first-in-class small molecule therapies for previously 'undruggable' cancer targets. The agreem... -
Drug Discovery & DDS
Biogen Pivots Post-Apellis Acquisition: Halts Most R&D, Concentrates on Commercial Assets
Endpoints News USA Overview Biogen has confirmed it will suspend or terminate "most" of Apellis Pharmaceuticals' research programs and lay off some employees following its $5.6 billion acquisition. This strategic pivot is part of integra... -
Drug Discovery & DDS
RQ Bio Secures $115M to Fast-Track Long-Acting Antibody RQB01, Revolutionizing Flu Prevention for Vulnerable Patients
GlobeNewswire UK Overview RQ Bio has successfully closed a $115 million (approximately £85.5 million) Series A funding round, led by Frazier Life Sciences, to accelerate the clinical development of RQB01. This long-acting antibody progra...